RadioRx, Inc, Mountain View, CA, USA.
Transl Oncol. 2012 Apr;5(2):66-71. doi: 10.1593/tlo.11307. Epub 2012 Apr 1.
As a short-lived radical that diffuses across membranes, rather than interacting with membrane-bound receptors, nitric oxide (NO) represents a significant departure from synthetically derived radiosensitizers. An endogenous compound, NO may equal or surpass its molecular cousin, oxygen, as a hypoxic radiosensitizer, through pleiotropic phenotypic effects on tumor perfusion, cell signaling, mitochondrial respiration, the fixation of radiation-induced damage, and the radioprotection of normal tissue. However, unlike oxygen, in the context of radiosensitization, the clinical role and utility of NO are poorly understood, with often contradictory and controversial reported effects: whether NO functions as a radiosensitizer may ultimately be contextual to the tumor microenvironment. This may make NO manipulation an ideal candidate for a personalized radiosensitization approach tailored to specific patient and tumor types/microenvironmental characteristics. Effective delivery of NO both systemically and directly to the tumor may be critical to the success of this approach. Compounds that release NO or NO precursors have the potential to drive innovation and result in a new fertile branch of the radiosensitizer tree.
作为一种短寿命的自由基,能够扩散穿过细胞膜,而不是与膜结合的受体相互作用,一氧化氮(NO)代表了与合成衍生的放射增敏剂的重大背离。NO 作为一种内源性化合物,可能与其分子表亲氧气一样,作为缺氧放射增敏剂,通过对肿瘤灌注、细胞信号转导、线粒体呼吸、辐射诱导损伤的固定以及正常组织的放射保护等方面的多效性表型效应来发挥作用。然而,与氧气不同,在放射增敏的背景下,NO 的临床作用和用途知之甚少,且常常存在相互矛盾和有争议的报道效应:NO 是否作为放射增敏剂起作用,最终可能取决于肿瘤微环境。这可能使 NO 的操纵成为一种理想的个性化放射增敏方法的候选方法,该方法可以针对特定的患者和肿瘤类型/微环境特征进行定制。NO 的全身性和直接递送至肿瘤的有效输送可能是该方法成功的关键。释放 NO 或其前体的化合物具有推动创新并产生放射增敏剂新分支的潜力。